Skip to main content
Fig. 6 | Genome Medicine

Fig. 6

From: Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes

Fig. 6

Differential drug response identified in GFRN phenotype heterogeneity. Boxplots of –log (EC50) drug response data from four drugs in the drug assay that show a differential drug response within growth factor phenotypes. a GSK1059615, a PI3K and mTOR inhibitor, caused an increase in response in samples within the survival phenotype classified as having high HER2 activity. b Lapatinib, a HER2 inhibitor, stimulated a stronger response in samples within the survival phenotype with high HER2 activity. c AG1478 and d gefitinib, EGFR inhibitors, caused an increased response in samples within the growth phenotype classified as having low BAD activity

Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us